Harrow Health Inc (HROW)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

102 WOODMONT BLVD NASHVILLE, TN 37215

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of non-invasive topically delivered medications. The company's lead topical drug candidate, Ketotransdel, utilizes its proprietary Transdel cream formulation to facilitate the passage of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the epidermis and into underlying tissues. Ketotransdel provides an alternative to the oral administration of cyclooxygenase-2 selective NSAIDs (COX-2 inhibitors) and non-selective NSAIDs. It has completed a Phase 1/2 trial for treating soft tissue pain and soreness in a delayed onset muscle soreness model with Ketotransdel. Transdel Pharmaceuticals also investigates other drug candidates and treatments for transdermal delivery using Transdel technology, including anesthetics, human hormone replacement, and anti-nausea medications. The company was founded in 1998 and is headquartered in La Jolla, California.

Data as of 2020-08-01
Market Cap140.392 Million Shares Outstanding25.619 Million Avg 30-day Volume287.899 Thousand
P/E Ratio Dividend Yield EPS-0.93
Price/Sales3.776 Price cash flow ratio78.5 Price free cash flow ratio-489.6
Book Value0.6 Price to Tangible Book11.33 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.03296
BETA0.862183 52-week High/Low7.92 / 3.33 Stddev0.204328
View SEC Filings from HROW instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 1 1 (0.07%)
13F Filers holding this stock: 57 20 (1.31%)
Aggregate 13F shares on 03/31/2020: 9.972 Million 7.866 Million
Aggregate 13F shares on 12/31/2019: 9.772 Million 7.417 Million
Percent change: 2.05% 6.04%
Funds creating new positions: 11 1
Funds Adding to an existing position: 18 7
Funds closing out their position: 12 7
Funds reducing their position: 19 8
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding HROW (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HROW BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

284 Thousand total shares from 9 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

OPALEYE MANAGEMENT INC.

  • 10% Owner
2,959,000 2020-07-10 6

LINDSTROM RICHARD L MD

  • Director
0 2020-06-25 1

BAUM MARK L CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-06-04 4

KAMMER ROBERT J

  • Director
0 2020-06-04 5

PRINCIPI ANTHONY

  • Director
0 2020-06-04 1

SPARKS TERESA

  • Director
0 2020-06-04 3

THORNLEY ANTHONY S

  • Director
0 2020-05-12 0

AUSTIN STEPHEN G

  • Director
91,987 2020-03-16 1

SWANN LYNN C

26,088 2020-02-18 0

LONGBOARD CAPITAL ADVISORS, LLC

CONRAD BRETT

  • 10% Owner
  • MANAGING MEMBER
3,777,318 2020-01-28 0

BOLL ANDREW R. CHIEF FINANCIAL OFFICER

  • Officer
0 2020-01-02 3

BONFIGLIO JOHN N CHIEF OPERATING OFFICER

  • Officer
37,500 2019-07-01 0

SAHAREK JOHN P. CHIEF COMMERCIAL OFFICER

  • Officer
0 2019-02-19 0

KENNY PETER C

  • Director
8,600 2017-05-17 0

EDWARDS CLAYTON D CHIEF OPERATING OFFICER

  • Officer
0 2017-04-13 0

NELSON WILLIAM H.

  • Director
0 2016-06-10 0

MILONI DONALD PAUL

  • 10% Owner
No longer subject to file 2015-05-18 0

BASSANI AUGUST SHELBY

  • Director
13,488 2014-09-04 0

FINNEGAN PAUL

  • Director
6,865 2013-06-27 0

ABRAMS JEFFREY J

  • Director
45,927 2013-06-27 0

SCHUPP JOACHIM PH CHIEF MEDICAL OFFICER

  • Officer
0 2013-04-01 0

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA, INC.

  • 10% Owner
832,682 2012-08-31 0

DERMASTAR INTERNATIONAL, LLC

  • 10% Owner
0 2012-06-29 0

LADONNIKOV ALEXEJ

  • 10% Owner
1,984,156 2012-02-28 0

BRAR BALBIR

  • Director
66,022 2012-01-23 0

NIDA TERRY CHIEF BUSINESS OFFICER

  • Officer
0 2010-02-26 0

SINGH JULIET CEO, DIRECTOR AND PRESIDENT

  • Officer
  • Director
  • 10% Owner
0 2009-06-18 0

LOMORO JOHN T CHIEF FINANCIAL OFFICER

  • Officer
0 2009-06-18 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

OPALEYE MANAGEMENT INC. - > 10% Owner by managed account

2020-07-12 P 1,900 $4.98 a 131,900 2,959,000.00 indirect

OPALEYE MANAGEMENT INC. - > 10% Owner by opaleye, l.p.

2020-07-12 P 19,000 $4.99 a 2,827,100 2,959,000.00 indirect

OPALEYE MANAGEMENT INC. - > 10% Owner by opaleye, l.p.

2020-07-11 P 46,800 $4.96 a 2,808,100 2,959,000.00 indirect

OPALEYE MANAGEMENT INC. - > 10% Owner by opaleye, l.p.

2020-07-10 P 45,000 $4.98 a 2,761,300 2,959,000.00 indirect

OPALEYE MANAGEMENT INC. - > 10% Owner by managed account

2020-07-09 P 5,000 $4.82 a 130,000 2,846,300.00 indirect

OPALEYE MANAGEMENT INC. - > 10% Owner by opaleye, l.p.

2020-07-09 P 25,000 $4.84 a 2,716,300 2,846,300.00 indirect

OPALEYE MANAGEMENT INC. - > 10% Owner by opaleye, l.p.

2020-07-08 P 65,000 $4.99 a 2,691,300 2,846,300.00 indirect

OPALEYE MANAGEMENT INC. - > 10% Owner by opaleye, l.p.

2020-07-07 P 41,300 $5.18 a 2,626,300 2,846,300.00 indirect

OPALEYE MANAGEMENT INC. - > 10% Owner by opaleye, l.p.

2020-06-19 P 35,000 $5.58 a 2,585,000 2,710,000.00 indirect
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments